Today's edition · Tuesday, November 3, 2026
Every story verifiedNo politics. Ever.No pop-ups
TodayLocalWorldHeroesAnimalsScienceCommunityHealth & TechMapQuizKindnessAnnouncementsKidsTopicsExplainersOn this dayCalendarGood NeighborHometown Heroes

TodayHealth & TechMichigan

Health & TechAnn Arbor, Michigan

Genetic testing led a Michigan man to a drug that stopped his pancreatitis attacks

After genetic testing found a rare triglyceride disorder, a Michigan man entered a trial of Tryngolza, approved by the FDA in June 2026. Michigan Medicine reports that decades of pancreatitis attacks then stopped. That is his course, not a result for every patient.

Verified · Source: Michigan MedicineNov 2, 2026 · 1 min read
How to help
Scientists in white coats working together at a laboratory bench
Illustrative photo of a medical laboratory. This is not the Michigan Medicine trial. Esculab / Wikimedia Commons · CC0

Read the original

The reporting lives at Michigan Medicine. Our summary is checked against it, and we link it on every story.

Genetic testing gave a Michigan man a name for a rare triglyceride disorder behind decades of pancreatitis attacks, Michigan Medicine reported. He then entered a clinical trial of Tryngolza, a drug the Food and Drug Administration approved in June 2026. In his case, the attacks stopped.

That is one patient's course after testing and a trial, reported by the university medical center in Ann Arbor. It does not show that the drug ends pancreatitis for every person who has it, or that it treats every disorder involving high triglycerides. The attacks stopping is what happened for him. It is not a measure of how long that change will hold, and it is not a result from a large comparison group in this account.

More good news

Other stories in the same neighborhood of kindness.